KNect365 is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


GigaGen seeks partners for antibody pipelines against 17 IO targets

Using its proprietary Surge platform, GigaGen is able to capture and interrogate natural immune systems rapidly and identify every antibody in circulation against virtually any cancer target. Speaking to Scrip at the Biotech Showcase, CEO David Johnson said he is now seeking partners for 17 distinct IO targets including common checkpoint inhibitors PD-1 and CTLA-4, and more novel targets such as TIM-3 and VISTA.

Get the latest news as it happens.